Three independent discounted-cash-flow-style models value Pacific Biosciences of California, Inc. every trading day. 1 of 3 currently price PACB above its market price.
| Free Cash Flow model | $-22.42 |
| Excess Profit model | $-35.99 |
| Residual Earnings model | $1,512,781,065,738,313.75 |
| Dividend Discount model | — |
| Piotroski F-Score | 3 / 9 |
| Return on invested capital | -76.8% |
| Net debt / EBITDA | — |
| Gross margin | +28.6% |
| Revenue CAGR | +7.6% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -9.3% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open PACB in StockKitty